PURPOSE: To develop physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics and drug-drug interactions (DDI) of pravastatin, using the in vitro transport parameters. METHODS: In vitro hepatic sinusoidal active uptake, passive diffusion and canalicular efflux intrinsic clearance values were determined using sandwich-culture human hepatocytes (SCHH) model. PBPK modeling and simulations were implemented in Simcyp (Sheffield, UK). DDI with OATP1B1 inhibitors, cyclosporine, gemfibrozil and rifampin, was also simulated using inhibition constant (Ki) values. RESULTS: SCHH studies suggested active uptake, passive diffusion and efflux intrinsic clearance values of 1.9, 0.5 and 1.2 μL/min/10(6)cells, respectively, for pravastatin. PBPK model developed, using transport kinetics and scaling factors, adequately described pravastatin oral plasma concentration-time profiles at different doses (within 20% error). Model based prediction of DDIs with gemfibrozil and rifampin was similar to that observed. However, pravastatin-cyclosporine DDI was underpredicted (AUC ratio 4.4 Vs ~10). Static (R-value) model predicted higher magnitude of DDI compared to the AUC ratio predicted by the PBPK modeling. CONCLUSIONS: PBPK model of pravastatin, based on in vitro transport parameters and scaling factors, was developed. The approach described can be used to predict the pharmacokinetics and DDIs associated with hepatic uptake transporters.
PURPOSE: To develop physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics and drug-drug interactions (DDI) of pravastatin, using the in vitro transport parameters. METHODS: In vitro hepatic sinusoidal active uptake, passive diffusion and canalicular efflux intrinsic clearance values were determined using sandwich-culture human hepatocytes (SCHH) model. PBPK modeling and simulations were implemented in Simcyp (Sheffield, UK). DDI with OATP1B1 inhibitors, cyclosporine, gemfibrozil and rifampin, was also simulated using inhibition constant (Ki) values. RESULTS: SCHH studies suggested active uptake, passive diffusion and efflux intrinsic clearance values of 1.9, 0.5 and 1.2 μL/min/10(6)cells, respectively, for pravastatin. PBPK model developed, using transport kinetics and scaling factors, adequately described pravastatin oral plasma concentration-time profiles at different doses (within 20% error). Model based prediction of DDIs with gemfibrozil and rifampin was similar to that observed. However, pravastatin-cyclosporine DDI was underpredicted (AUC ratio 4.4 Vs ~10). Static (R-value) model predicted higher magnitude of DDI compared to the AUC ratio predicted by the PBPK modeling. CONCLUSIONS: PBPK model of pravastatin, based on in vitro transport parameters and scaling factors, was developed. The approach described can be used to predict the pharmacokinetics and DDIs associated with hepatic uptake transporters.
Authors: Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang Journal: Nat Rev Drug Discov Date: 2010-03 Impact factor: 84.694
Authors: Mikko Niemi; Katja A Arnold; Janne T Backman; Marja K Pasanen; Ute Gödtel-Armbrust; Leszek Wojnowski; Ulrich M Zanger; Pertti J Neuvonen; Michel Eichelbaum; Kari T Kivistö; Thomas Lang Journal: Pharmacogenet Genomics Date: 2006-11 Impact factor: 2.089
Authors: Mikko Niemi; Pertti J Neuvonen; Ute Hofmann; Janne T Backman; Matthias Schwab; Dieter Lütjohann; Klaus von Bergmann; Michel Eichelbaum; Kari T Kivistö Journal: Pharmacogenet Genomics Date: 2005-05 Impact factor: 2.089
Authors: Manthena V Varma; Charles J Rotter; Jonathan Chupka; Kevin M Whalen; David B Duignan; Bo Feng; John Litchfield; Theunis C Goosen; Ayman F El-Kattan Journal: Mol Pharm Date: 2011-07-11 Impact factor: 4.939
Authors: R J Ptachcinski; R Venkataramanan; J T Rosenthal; G J Burckart; R J Taylor; T R Hakala Journal: Clin Pharmacol Ther Date: 1985-09 Impact factor: 6.875
Authors: Michael J Knauer; Bradley L Urquhart; Henriette E Meyer zu Schwabedissen; Ute I Schwarz; Christopher J Lemke; Brenda F Leake; Richard B Kim; Rommel G Tirona Journal: Circ Res Date: 2009-11-25 Impact factor: 17.367
Authors: Bhagwat Prasad; Raymond Evers; Anshul Gupta; Cornelis E C A Hop; Laurent Salphati; Suneet Shukla; Suresh V Ambudkar; Jashvant D Unadkat Journal: Drug Metab Dispos Date: 2013-10-11 Impact factor: 3.922
Authors: Manthena V S Varma; Yurong Lai; Bo Feng; John Litchfield; Theunis C Goosen; Arthur Bergman Journal: Pharm Res Date: 2013-03-06 Impact factor: 4.200
Authors: John D Clarke; Rhiannon N Hardwick; April D Lake; Andrew J Lickteig; Michael J Goedken; Curtis D Klaassen; Nathan J Cherrington Journal: J Hepatol Date: 2014-03-05 Impact factor: 25.083
Authors: M J Zamek-Gliszczynski; C A Lee; A Poirier; J Bentz; X Chu; H Ellens; T Ishikawa; M Jamei; J C Kalvass; S Nagar; K S Pang; K Korzekwa; P W Swaan; M E Taub; P Zhao; A Galetin Journal: Clin Pharmacol Ther Date: 2013-02-25 Impact factor: 6.875